Base de dados : LILACS
Pesquisa : D03.383.129.578.840.249.184 [Categoria DeCS]
Referências encontradas : 258 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 26 ir para página                         

  1 / 258 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Costa Rica
Texto completo
Texto completo
Id: biblio-1002560
Autor: Carvajal Carvajal, Carlos.
Título: Bilirrubina: metabolismo, pruebas de laboratorio e hiperbilirrubinemia / Bilirubin: metabolism, laboratory tests and hyperbilirubinemia
Fonte: Med. leg. Costa Rica;36(1):73-83, ene.-mar. 2019.
Idioma: es.
Resumo: Resumen La bilirrubina es el producto final de la degradación del grupo hem. La bilirrubina no conjugada (BNC) se forma en las células retículoendoteliales, transportada al hígado, donde es conjugada a glucurónidos y secretada a los canalículos. La BNC se solubiliza en el suero por medio de su fuerte unión con la albúmina. La unión bilirrubina-albúmina es una función de las concentraciones de la albúmina y de la bilirrubina y de la afinidad de unión por la bilirrubina. La fracción de bilirrubina no unida o bilirrubina libre plasmática (Bf) se incrementa significativamente conforme el nivel de bilirrubina sérica total (BST) alcanza la capacidad de unión de la albúmina. La Bf es considerada un mejor indicador de neurotoxicidad que la BST, a causa de que solamente la bilirrubina libre puede cruzar la barrera hematoencefálica. En la práctica médica la bilirrubina es un marcador de disfunción hepática, colestasis o enfermedad hemolítica. Una variedad de factores limita la sensibilidad y la especificidad de la medición de la bilirrubina para detectar anormalidades: lipemia, hemólisis, exposición a la luz visible y el estado de ayuno. La hiperbilirrubinemia puede ser clasificada como prehepática, hepática y poshepática, y esto brinda un marco útil para identificar la causa subyacente. Además, hay bilirrubina conjugada y no conjugada. La hiperbilirrubinemia y la ictericia neonatales se presentan en casi todos los recién nacidos y puede ser benigna si su progresión a hiperbilirrubinemia es reconocida, monitoreada y prevenida o tratada en una manera oportuna.

Abstract Bilirubin is the end product of heme breakdown. Unconjugated bilirubin (UB) is formed in reticuloendothelial cells, transported to the liver where it is conjugated to glucuronides, and then secreted into the canaliculi. UB is solubilized in serum via very tight linkage to albumin. Bilirubin-albumin binding is a function of the concentration of bilirubin and albumin and the binding affinity for bilirubin. The fraction of unbound bilirubin or plasma free bilirubin (Bf) increases significantly as the total serum bilirubin (TSB) level approaches the binding capacity of albumin. Bf is thought to be better indicator of neurotoxicity than TSB, because only plasma free bilirubin can cross the blood-brain barrier. In medical practice bilirubin is a marker of liver dysfunction, cholestasis or hemolytic disease. A variety of factors limit both the sensitivity and the specificity of bilirubin measurement to detect the abnormalities: lipemia, hemolysis, exposure of visible light and fasting state. Hyperbilirubinemia can be categorised as prehepatic, hepatic or poshepatic, and this provides a useful framework for identifying the underlying cause. In addition, there are conjugated and unconjugated bilirubin. Neonatal hyperbilirubinemia and jaundice occur in almost all newborns and may be benign if its progression to extreme hyperbilirubinemia is recognized, monitored and prevented or managed in a timely manner.
Descritores: Bilirrubina
Biomarcadores
Hiperbilirrubinemia
Icterícia
Testes de Função Hepática
Limites: Humanos
Tipo de Publ: Revisão
Responsável: CR1.1 - BINASSS - Biblioteca Nacional de Salud y Seguridad Social


  2 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Barbosa, Alfredo José Afonso
Alberti, Luiz Ronaldo
Texto completo
Id: biblio-973473
Autor: Magalhães, Maria Angélica Baron; Petroianu, Andy; Barbosa, Alfredo José Afonso; Figueiredo, Juliano Alves; Alberti, Luiz Ronaldo; Ribas Filho, Jurandir Marcondes.
Título: Effects of different periods of gastric ischemia on liver as a remote organ
Fonte: Acta cir. bras;33(11):964-974, Nov. 2018. tab, graf.
Idioma: en.
Resumo: Abstract Purpose: To evaluate the hepatic changes associated with gastric ischemia. Methods: Thirty male rabbits were studied, distributed in 3 groups (n=10). Group 1: ligature and section of the gastric vasculature and removal of the liver after three hours; Group 2: ligature and section of the gastric vasculature and removal of the liver after 6 hours; Group 3: ligature and section of the gastric vasculature and removal of the liver after 12 hours. Blood samples were collected immediately before surgery and after the determined time of ischemia in each group to evaluate the hepatic function. After the death of the rabbits, the liver was removed for macro and microscopic study. Results: An increase in aminotransferases and bilirubin occurred in groups 2 and 3. Total protein and albumin diminished in all of the animals. All of the rabbits from groups 2 and 3 presented hepatocellular necrosis. Conclusion: The devascularization of the stomach for a period of above three hours is associated with hepatic morphological and functional disorders.
Descritores: Estômago/irrigação sanguínea
Estômago/patologia
Isquemia/complicações
Fígado/patologia
-Aspartato Aminotransferases
Valores de Referência
Fatores de Tempo
Bilirrubina/sangue
Albumina Sérica/análise
Traumatismo por Reperfusão/patologia
Distribuição Aleatória
Alanina Transaminase
Fosfatase Alcalina
gama-Glutamiltransferase
Isquemia/patologia
Fígado/irrigação sanguínea
Hepatopatias/etiologia
Hepatopatias/patologia
Necrose
Limites: Animais
Masculino
Coelhos
Responsável: BR1.1 - BIREME


  3 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1010871
Autor: Luo, Wei-wei; Zhou, Xue-ling; Wang, Qing-qing; Shao, Yan-jing; Li, Ze-ming; Zhao, Dong-kang; Yu, Shui-ping.
Título: The application of Compont gel in chronic obstructive jaundice rats model
Fonte: Acta cir. bras;34(5):e201900504, 2019. tab, graf.
Idioma: en.
Projeto: Guangxi Medical and Health Appropriate Technology Research and Development Project; . Project Plan Document of Guangxi Key Laboratory Construction.
Resumo: Abstract Purpose: To establish a new rat model, the pathogenesis of which is closer to the clinical occurrence of chronic obstructive jaundice with liver fibrosis. Methods: 90 SD rats were randomly divided into 3 groups. Group A common bile duct ligation, group B common bile duct injection compont and group C injection saline. The serum of three groups was extracted, and the liver function was detected by ELISA. HE staining, Masson staining and immunohistochemistry were used to detect liver pathology. Results: Group B showed a fluctuant development of jaundice, obstructive degree reached a peak at 2 weeks, and decreased from 3 weeks. HA, LA and PCIII were significantly higher than control group. 3 weeks after surgery, liver tissue fibrosis occurred in group B, and a wide range of fiber spacing was formed at 5 weeks. Immunohistochemistry showed that hepatic stellate cells were more active than the control group. Conclusion: Intra-biliary injection of Compont gel is different from the classic obstructive jaundice animal model caused by classic bile duct ligation, which can provide an ideal rat model of chronic obstructive jaundice with liver fibrosis.
Descritores: Ductos Biliares/efeitos dos fármacos
Modelos Animais de Doenças
Géis/administração & dosagem
Cirrose Hepática/induzido quimicamente
-Aspartato Aminotransferases/sangue
Valores de Referência
Compostos Azo
Fatores de Tempo
Ductos Biliares/patologia
Bilirrubina/análise
Albumina Sérica/análise
Ensaio de Imunoadsorção Enzimática
Imuno-Histoquímica
Distribuição Aleatória
Reprodutibilidade dos Testes
Ratos Sprague-Dawley
Amarelo de Eosina-(YS)
Icterícia Obstrutiva/induzido quimicamente
Icterícia Obstrutiva/patologia
Fosfatase Alcalina/sangue
gama-Glutamiltransferase/sangue
Injeções
Cirrose Hepática/patologia
Verde de Metila
Limites: Animais
Feminino
Tipo de Publ: Estudo de Avaliação
Responsável: BR1.1 - BIREME


  4 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887165
Autor: Jardim, Márcio Martins Lobo; Diniz, Ticiana Andrade Castelo Branco; Cunha, Thaís Amaral Carneiro; Valente, Neusa Yurico Sakai.
Título: Subcorneal pustular dermatosis in the pediatric age
Fonte: An. bras. dermatol;93(1):116-118, Jan.-Feb. 2018. graf.
Idioma: en.
Resumo: Abstract: Subcorneal pustular dermatosis is a rare pustular eruption which occurs mainly in middle-aged women and rarely during childhood. We report a case of a 15-year-old female with a 4-year history of pustular lesions on the proximal region of the upper limbs with subsequent impairment of the trunk. Physical examination revealed small pustules distributed on the trunk and proximal region of the limbs. Histopathology showed a subcorneal pustule and direct immunofluorescence for IgA, IgM, IgG and fibrinogen was negative, confirming the diagnosis of subcorneal pustular dermatosis. The patient was treated with dapsone with good clinical response after one month. Subcorneal pustular dermatosis is a rare condition and there are only isolated cases reported in the literature in pediatric patients. Thus, we discuss the main clinical aspects and treatment response of this condition during childhood.
Descritores: Dermatopatias Vesiculobolhosas/tratamento farmacológico
Dapsona/uso terapêutico
Fármacos Dermatológicos/uso terapêutico
-Bilirrubina/sangue
Hemoglobinas/análise
Dermatopatias Vesiculobolhosas/diagnóstico
Dermatopatias Vesiculobolhosas/patologia
Limites: Humanos
Feminino
Adolescente
Tipo de Publ: Relatos de Casos
Responsável: BR1.1 - BIREME


  5 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1051461
Autor: Casale, Roberto; Pascale, Julián; Varela, Silvana; López, Mariana; Parrilla, Rocío; Monaco, Antonio.
Título: Niveles plaquetarios y marcadores de disfunción endotelial multiorgánica en síndrome HELLP / Platelet levels and multiorganic endothelial dysfunction markers in the Hellp Syndrome (Hemolysis, elevated liver enzimes, low platelets)
Fonte: Prensa méd. argent;104(4):168-180, Jun2018. tab, graf.
Idioma: es.
Resumo: HELLP syndrome (hemolysis, elevated liver enzimes, low platelets count) is one of the major complications of the progression of thrombotic microangiopathies characterized by thrombocytopenia, hemolistic anemia and organic dysfunction. It can be found in between 0,5 - 0,9 % of all pregnancies, and between 4- 14 % in all those women who develop preeclampsia. The general objectives of this report were to describe the relationship existing between the platelet levls and the organic endothelial dysfunction because of the HELLP syndrome, and to determine the perinatal results, during the 10 yr. period of the study, in patients that were assited between 2007 and 2016.
Descritores: Contagem de Plaquetas
Pré-Eclâmpsia/fisiopatologia
Fibrina
Síndrome HELLP/fisiopatologia
Síndrome HELLP/mortalidade
Síndrome HELLP/terapia
Assistência Perinatal
Endotélio/fisiopatologia
-Bilirrubina
Limites: Humanos
Feminino
Gravidez
Adulto
Tipo de Publ: Estudo Observacional
Responsável: AR392.1 - Biblioteca


  6 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827649
Autor: Tabushi, Fernando Issamu; Stueber, Melissa Spena; Polonio, Benur; Repka, João Carlos Domingues; Ioshii, Sérgio Ossamu; Nassif, Paulo Afonso Nunes.
Título: Vertical gastrectomy in overweight and non-overweight rats
Fonte: Acta cir. bras;31(10):689-693, Oct. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To compare the two lines suture (total and seromuscular) after partial gastrectomy in normal and overweight rats. METHODS: Forty Wistar rats were distributed in two groups. Group A received normal diet; group B, normal diet and supplementation with saccharose in the water. When group B progressed to a statistically greater weight than the animals of group A, the experiment (sleeve-like gastrectomy) was conducted with gastrorraphy in two sutures lines (total and seromuscular).The animals were distributed into two subgroups of 10. A1 and A2 subgroups were sacrificed at 7 and 14 days postoperatively as well as B1 and B2. Mortality, morbidity, complications attributed to the gastric suture, biochemical dosages, Lee index, macroscopy, weight of retroperitoneal and gonadal fat, optical microscopy with hematoxylin-eosin and picrosirius-red, were the evaluation parameters. RESULTS: The overweight group achieved statistically greater weight after 16 weeks in induced obesity; there was no mortality or complications with clinical consequences attributable to morbidity. The overweight group had statistically greater weight of gonadal and retroperitoneal fat. The difference was observed in urea, albumin, total cholesterol and indirect bilirubin. CONCLUSION: There was no outcome difference between the overweight and non-overweight group in two suture lines in gastrorrhaphy after sleeve-like gastrectomy.
Descritores: Cicatrização
Técnicas de Sutura
Sobrepeso/cirurgia
Gastrectomia/métodos
-Período Pós-Operatório
Valores de Referência
Fatores de Tempo
Ureia/sangue
Bilirrubina/sangue
Albumina Sérica/análise
Colesterol/sangue
Resultado do Tratamento
Ratos Wistar
Laparotomia/métodos
Limites: Animais
Masculino
Tipo de Publ: Estudo Comparativo
Responsável: BR1.1 - BIREME


  7 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-777096
Autor: Çakır, Tuğrul; Aslaner, Arif; Tekeli, Seçkin Özgür; Güneş, Kasım; Kinaci, Erdem; Doğan, Uğur; Tekeli, Feyza; Akyüz, Cebrail; Koç, Süleyman; Yılmaz, Necat.
Título: Grape seed protects cholestatic rats liver from ischemia/reperfusion injury
Fonte: Acta cir. bras;31(3):183-189, Mar. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT PURPOSE: To determine the effect of grape-seed extract against ischemia/reperfusion injury in cholestatic liver. METHODS: Eighteen Wistar albino rats were divided into three groups. In control and study groups, cholestasis was provided by bile duct ligation. Seven days later, the rats were subjected to 30 min hepatic ischemia, followed by 60 min of reperfusion. Oral administration of 50 mg/kg/day grape-seed extract was started 15 days before bile duct ligation and continued to the second operation in the study group. Serum, plasma and liver samples were taken. Laboratory analysis, tissue gluthation, malondialdehyde, myeloperoxidase levels and histopathological examination were performed. RESULTS: Significant decrease in liver gluthation level and significant increase in malondialdehyde level and myeloperoxidase activity were observed after ischemia/reperfusion in cholestatic rats. Serum and plasma levels for laboratory analysis were also significantly higher in cholestatic I/R group. Hepatic necrosis and fibrosis were detected in histopathological examination. Oral grape-seed extract administiration reversed all these parameters and histopathological findings except serum bilirubin levels. CONCLUSION: Oral grape-seed extract treatment can improve liver functions and attenuate the inflammation and oxidative stress in cholestatic ischemia/reperfusion injury.
Descritores: Traumatismo por Reperfusão/prevenção & controle
Colestase/complicações
Extrato de Sementes de Uva/farmacologia
Antioxidantes/farmacologia
-Aspartato Aminotransferases/efeitos dos fármacos
Aspartato Aminotransferases/metabolismo
Bilirrubina/metabolismo
Traumatismo por Reperfusão/metabolismo
Colestase/metabolismo
Colestase/patologia
Ratos Wistar
Estresse Oxidativo/efeitos dos fármacos
Lactato Desidrogenases/efeitos dos fármacos
Lactato Desidrogenases/metabolismo
Alanina Transaminase/efeitos dos fármacos
Alanina Transaminase/metabolismo
Modelos Animais de Doenças
Inflamação/metabolismo
Fígado/efeitos dos fármacos
Fígado/patologia
Limites: Animais
Masculino
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  8 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1026149
Autor: Alfieri, Gabriela; Mir Villamayor, Ramón; Genes de Lovera, Larissa Eliana; Otazo Arévalos, Edaniela Maria; Miño Moreno, Sara Graciela; Bordón Dure, Jeremías Pedro.
Título: Aplicación del bilirrubinómetro no invasivo en recién nacidos / Application of non-invasive bilirubinometry in newborns
Fonte: Pediatr. (Asunción);46(3):159-164, Set-Dic 2019.
Idioma: es.
Resumo: Introducción: Las pautas para prevención y tratamiento de hiperbilirrubinemia neonatal recomiendan medición de bilirrubina sérica total (BST) o bilirrubina transcutánea (BTc) para determinar el grado de ictericia antes del alta del recién nacido (RN); ésta última no invasiva, proporciona información instantánea y de calidad superior a la evaluación clínica. A pesar de ello aún no ha sido aplicada en forma sistemática en los hospitales de Paraguay. Objetivo: evaluar la aplicación en nuestro medio de la medición de bilirrubinemia transcutánea antes del alta correlancionando con la bilirrubina sérica. Materiales y Métodos: Estudio observacional, descriptivo con componente analítico, de corte transversal. Fueron incluidos RN con edad gestacional ≥ a 35 semanas, con peso ≥ a 2000 gramos, luego de las 24 hs de vida hasta los 8 días; bajo consentimiento informado de los padres, durante un año. Los datos fueron consignados en una planilla de Microsoft Excel y procesado por el software IBM SPSS Statistics ®. Resultados: De 271 RN que ingresaron al estudio, en la primera medición con el Bilirrubinómetro transcutáneo, cumplían con criterios para toma de bilirrubina sérica 90 (33,2%) de ellos. En los restantes 181 RN (66,8%), los datos emparejados no estaban disponibles debido a que siguiendo las recomendaciones de las guías actuales no fue necesario medir la bilirrubina sérica. El valor del coeficiente de correlación para la primera medición fue r = 0.574. Para la segunda medición las medidas emparejadas estaban disponibles para 131 RN. En este caso se encontró correlación positiva entre ambos métodos de 0,590. Conclusión: La bilirrubina transcutánea puede utilizarse en forma rápida, segura y válida, como un test de screening para la detección de hiperbilirrubinemia y podría evitar una proporción importante de toma de muestras sanguíneas, mejorando la seguridad del paciente.

Introduction: The guidelines for prevention and treatment of neonatal hyperbilirubinemia recommend measurement of total serum bilirubin (BST) or transcutaneous bilirubin (BTc) to determine the degree of jaundice before discharge of the newborn (NB); the latter non-invasive method provides instant information which is superior to the clinical evaluation. Despite this, it has not yet been systematically applied in hospitals in Paraguay. Objective: to evaluate transcutaneous measurement of bilirubin concentration as compared to serum bilirubin levels prior to discharge in our setting. Materials and Methods: This was an observational, cross-sectional, descriptive study with an analytical component. For a period of one year, we tracked NBs with a gestational age ≥ 35 weeks, weighing ≥ 2000 grams, from 24 hours of life until 8 days of life, obtaining the informed consent of the parents. The data was entered in a Microsoft Excel spreadsheet and processed by the IBM SPSS Statistics ® software. Results: Of 271 NBs who entered the study, 90 (33.2%) met criteria for measurement of serum bilirubin at their first measurement with the transcutaneous bilirubinometer. In the remaining 181 RN (66.8%), the paired data were not available as measurement of serum bilirubin was not required per the recommendations of current guidelines. The correlation coefficient value for the first measurement was r = 0.574. For the second measurement, paired measurements were available for 131 NBs. In this case, a positive correlation was found between both methods of 0.590. Conclusion: Transcutaneous bilirubin can be used quickly, safely and accurately as a screening test for the detection of hyperbilirubinemia and could avoid a significant proportion of blood sampling, improving patient safety.
Descritores: Bilirrubina
Recém-Nascido
Hiperbilirrubinemia Neonatal
Hiperbilirrubinemia
Responsável: PY30.1 - Biblioteca


  9 / 258 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-552528
Autor: Blasco, Pablo Gonzáles(org); Levites, Marcelo Rozenfeld(org); Mônaco, Cauê(org).
Título: Avaliação visual não é confiável para estimativa de níveis de bilirrubina em recém-nascidos / Visual rating is not reliable for level estimation of bilirubin in newborns
Fonte: Diagn. tratamento;14(1):32-32, jan.-mar. 2009.
Idioma: pt.
Resumo: A avaliação clínica visual de recém-nascidos ictéricos não é uma maneira confiável de se estimar a bilirrubina sérica total.
Descritores: Bilirrubina
Recém-Nascido
Responsável: BR12.1 - Biblioteca Setorial da Ciências da Saúde


  10 / 258 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-886094
Autor: Eik, Luciana Carmen; Buscetti, María Guillermina; Di Camillo, Ignacio María; Medina, Yanina Soledad; Di Pinto, Paola; Minghetti, Erica; Obando, Daniela; Díaz Weiss, María Pía; Garri Zaccaria, Mara; Rocha, Daniela; Gutiérrez, Alejandra; Rementa, Ezequiel Hernán.
Título: Estudio de la interferencia por hemólisis en la determinación de bilirrubina total / Hemolysis interference study in determination of total bilirubin / Estudo da interferência por hemólise na determinação de bilirrubina total
Fonte: Acta bioquím. clín. latinoam;51(1):7-15, mar. 2017. ilus, graf, tab.
Idioma: es.
Resumo: La hemólisis es una causa frecuente de rechazo de muestras que genera un sesgo negativo en la determinación de bilirrubina total (BT). Los objetivos de este trabajo fueron determinar el grado de hemólisis (GH) para reemplazar la inspección visual subjetiva, establecer la magnitud de su interferencia y conocer la concentración inicial de hemoglobina a partir de la cual se produce interferencia clínicamente relevante (ICR). Se recolectaron sueros con diferentes concentraciones de BT. Se preparó un hemolizado para generar distintas concentraciones de interferente. Se cuantificó la BT mediante el método de diclorofenildiazonio en los sueros con las diferentes concentraciones de hemoglobina y se determinó GH midiendo absorbancia a 578 nm. Se consideró ICR cuando se superó la máxima inexactitud deseable. Para cada nivel de BT se determinó la concentración de hemoglobina máxima aceptable (CHbmáx aceptable) por sobre la cual se considera ICR. La Abs578 permitió definir cuatro GH (GH1, GH2, GH3 y GH4). A partir de los interferogramas se determinó la CHbmáx aceptable para cada nivel de BT; ésta mostró un aumento lineal con la BT. A partir de 14,8 mg/dL de BT no se encontró ICR en los rangos estudiados. El GH permite tomar conductas objetivas ante muestras hemolizadas según el algoritmo propuesto.

Hemolysis is a common cause for rejection of samples that generates a negative bias in total bilirubin (TB) determination. The objectives of this study were to determine the hemolysis degree (HD) to replace the subjective visual inspection, to establish the extent of their interference and to meet the initial hemoglobin concentration from which clinically relevant interference (CRI) occurs. Sera was collected at different TB concentrations.Hemolysate was prepared to generate different concentrations of interfering. TB was quantified by dichlorophenyldiazonium method in sera with several hemoglobin concentrations, and DH was determined by measuring absorbance at 578 nm (Abs578). CRI was considered when it exceeded the maximum desirable inaccuracy. For each TB level, the maximum acceptable concentration of hemoglobin (CHbmáx acceptable) above which ICR is considered was determined.The Abs578 made it possible to define four DH (DH1, DH2, DH3 and DH4). The CHbmax acceptable was determined for each level of TB from the interferograms; it showed a linear increase with TB. From 14,8 mg/dL BT, CRI was not found in the ranges studied. The DH makes it possible to have objective behaviours in hemolyzed samples according to the proposed algorithm.

A hemólise é uma causa frequente de rejeição de amostras que gera um viés negativo na determinação da bilirrubina total (BT). Os objetivos deste estudo foram: determinar o grau de hemólise (GH) para substituir a inspeção visual subjetiva, estabelecer a extensão da sua interferência e conhecer a concentração inicial de hemoglobina a partir da qual ocorre a interferência clinicamente relevante (ICR). Foram coletados soros com diferentes concentrações de BT. Um hemolisado foi preparado para gerar diferentes concentrações de interferente. Foi quantificada a BT pelo método de diclorofenil diazônio nos soros com as diferentes concentrações de hemoglobina e foi determinado o GH medindo a absorvância a 578 nm (Abs578). ICR foi considerada quando se superou a máxima inexatidão desejável. Para cada nível de BT foi determinada a concentração de hemoglobina máxima aceitável (CHbMax aceitável) acima da qual é considerada ICR. A Abs578 permitiu definir quatro GH (GH1, GH2, GH3 e GH4). A partir dos interferogramas se determinou a CHbMax aceitável para cada nível de BT; ela apresentou um aumento linear com a BT. A partir de 14,8 mg/dL de BT, a ICR não foi encontrada nos intervalos estudados. O GH permite ter condutas objetivas diante de amostras hemolisadas de acordo com o algoritmo proposto.
Descritores: Hemoglobinas/análise
Hemólise
-Controle de Qualidade
Bilirrubina
Técnicas de Laboratório Clínico/métodos
Limites: Humanos
Responsável: AR1.1 - Biblioteca Rafael Herrera Vegas



página 1 de 26 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde